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A B S T R A C T
Rare sugar syrup is a sweetener obtained from high-fructose corn syrup under slightly al-
kaline conditions, which promotes the formation of rare sugars. Here, the physiological impact
and safety of rare sugar syrup in humans was investigated by a randomized double-blind
parallel experiment.Thirty-four subjects with an average body mass index of 25.6 kg/m2 were
divided into two groups. Subjects consumed either a test drink containing rare sugar syrup
or an isocaloric control drink containing high-fructose corn syrup on a daily basis for 12
weeks. Results showed significant decreases in body weight, body fat percentage and waist
circumference in the rare sugar syrup group compared to the control. No adverse events
with regard to hepatic and renal function or blood parameters were observed. Our study
conclusively suggests, for the first time, that rare sugar syrup is a safe sweetener, and that
continuous consumption of this syrup could help weight management.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/3.0/).
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1. Introduction
High-fructose corn syrup (HFCS) and high intensity sweeten-
ers are used in a wide range of food and beverage products.
The rise in these consumption, however, is reported to be
associated with the growing risk of diabetes and obesity in the
United States (Gross, Li, Ford, & Liu, 2004; Swithers, 2013).
Because these issues relate to complex factors, such as
appetite, excessively consumed amount, kinds of carbohy-
drate, and genetic or social background of consumer, it is needed
to cautiously discuss and propose a solution to the social
demand that is the development of better sweeteners smooth-
ing these problems.
Recently, some interesting biological properties have been
reported for rare sugars. ‘The International Society of Rare
Sugars’ defined rare sugars as monosaccharides and their de-
rivatives that are present in limited quantities in nature. For
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example, allulose (psicose) is a rare sugar that has been well-
studied in terms of its efficacy, safety and production using
microorganisms. Allulose has nutritional benefits such as pre-
vention of diabetes (Chung, Oh, & Lee, 2012; Matsuo & Izumori,
2009) and improvement of lipidmetabolism (Matsuo et al., 2001).
In addition, the inclusion of around 4% allulose in HFCS sup-
presses abdominal fat accumulation caused by the long-
term ingestion of HFCS (Yamada et al., 2010).
As a natural and economically-feasible method for obtain-
ing syrup containing around 5% allulose, the quantity of which
is sufficient to suppress fat accumulation,we reisomerized HFCS
under mildly-basic conditions, similar to those used in food
processing applications such as sugar refining. This method
produces other monosaccharides, such as allose, sorbose and
mannose, which have been reported to improve lipid and car-
bohydrate metabolism or immune function (Kimura et al., 2005;
Toyota, Fukushi, Katoh, Orikasa, & Suzuki, 1989; Yamada et al.,
2014).
The obtained syrup containing rare sugars, called rare sugar
syrup (RSS), has 90% of the sweetness of sucrose, and with a
richer and cleaner taste than HFCS. Accordingly, we reasoned
that RSS might provide an alternative to HFCS, which may
reduce the likelihood of obesity caused by the consumption
of HFCS.
We previously tested the safety and efficacy of RSS for daily
use as a sweetener in a series of feeding experiments using
rats. Our study showed ingestion of RSS caused a reduction
in body weight and abdominal fat with no detectable adverse
effects (Iida et al., 2013; Matsuo et al., 2011). However, de-
tailed information concerning the safety and efficacy of RSS
for humans is being reported now for the first time. Based on
our previous animal study, we conducted this experiment in
humans to know more about an effective safe dose of rare
sugar syrup, and to evaluate biomarkers during long-term
consumption.
2. Materials and methods
2.1. Subjects
This study was approved by the ethics committee of Isogo
Central Hospital (Kanagawa, Japan) in accordance with the spirit
of the Declaration of Helsinki, and conducted under the su-
pervision of the principle investigator. Informed consent was
obtained from 34 volunteers (17 males and 17 females) with
an average BMI score of 25.6 kg/m2 (22–63 years old).A BMI score
of more than 25 kg/m2 is considered as obese as defined by the
Japan Society for the Study of Obesity. Exclusion criteria in-
cluded people with hepatic or renal dysfunction. Subjects
participating in this study were randomly divided into two
groups by theminimizationmethod based on inspectedmedical
centers, age, gender, BMI, body weight, body fat ratio and waist
circumference. Other background details for each group are
given in Table 1.
2.2. Experimental diets
The compositions of RSS and HFCS were analyzed by high per-
formance liquid chromatography with a MCI GEL CK 08EC
column (8 i.d. × 300 mm; Mitsubishi Chemical Corporation) and
refractive index detector. RSS was composed of 44.3% glucose,
31.9% fructose, 6.0% allulose and 17.8% other saccharides, in
which 7.5% mannose and sorbose were detected as non-
dividable peaks and 4.6% oligosaccharides were also detected.
The oligosaccharides analyzed were primarily disaccharides
(3.7%) including 0.7% maltose, 1.2% isomaltose, and 0.9%
maltulose derived from oligosaccharides in HFCS (Osaki &
Yoshino, 1982; Shiraishi, Kawakami, & Kusunoki, 1985). As a
reference, we confirmed around 1% allose in RSS using other
method. HFCS was composed of 41.8% glucose, 52.3% fruc-
tose and 5.9% oligosaccharides.
The energy exchange ratios of glucose and fructose are
4 kcal/g, and that of allulose is 0 kcal/g. Other saccharides for
which the energy exchange ratios were not determined were
calculated as 4 kcal/g based on the maximum calorie ob-
tained for the carbohydrate. The test drink containing 30 g of
RSS (114 kcal) and the control drink containing 28 g of HFCS
(114 kcal) as dry solid base were then used as the experimen-
tal diets. Each experimental diet had the same calorific value
and was prepared in the form of an identical 200 g jelly drink,
with an indistinguishable flavor and color.
HFCS used as the sweetener for the control drink was pur-
chased from Nihon Shokuhin Kako Co., Ltd. (Tokyo, Japan). RSS
used for the test drink was made by Matsutani Chemical In-
dustry, Co., Ltd. (Hyogo, Japan).
2.3. Study design
The experiment was based on a randomized double-blind, two-
group parallel, placebo-controlled comparison study. The 20-
week study period comprised 4 weeks for pre-treatment
observation, 12 weeks for treatment, and 4 weeks for post-
treatment observation. During the treatment phase the subjects
consumed either a test drink or a control drink 30 minutes
before breakfast on a daily basis. Subjects were instructed to
make seven scheduled visits to the medical center for testing
as follows: firstly at the beginning of the pre-treatment obser-
vation period and then during weeks 0, 2, 4, 8 and 12 of the
treatment period, and finally at the end of the post-treatment
observation period.
During each visit body weight, body fat ratio, waist circum-
ference, hip circumference, systolic blood pressure and diastolic
blood pressure were measured and blood and urine samples
were collected. Each subject was interviewed by a doctor to in-
vestigate any subjective symptoms in body condition (e.g.,
Table 1 – Background of the subjects.
Control RSS
Number of subjects 17 17
Male–female ratio Male: 9, female: 8 Male: 8, female: 9
Age (years) 42.4 ± 2.6 41.7 ± 2.8
Weight (kg) 70.4 ± 2.5 70.2 ± 3.0
Height (cm) 165.8 ± 2.6 165.7 ± 2.5
BMI (kg/m2) 25.6 ± 0.6 25.4 ± 0.6
Body fat ratio (%) 28.4 ± 1.7 28.2 ± 2.1
Waist circumference (cm) 83.9 ± 2.6 84.7 ± 2.7
Data are expressed as mean ± SEM.
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headache, dizziness, gastric problems) and/or any changes in
daily habits.
All measurements of blood and urine collection were taken
by SRL, Inc. Co., Ltd. (Tokyo, Japan). The laboratory param-
eters tested were as follows: white blood cells, red blood cells,
hemoglobin, hematocrit, platelets, alkaline phosphatase (ALP),
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), lactase dehydrogenase (LDH), γ-glutamyl transpeptidase
(γ-GTP), cholinesterase, creatine phosphokinase (CPK), total
protein (TP), serum amylase, albumin (Alb), albumin globulin
to ratio (A/G), total bilirubin, direct bilirubin, indirect biliru-
bin, urea nitrogen (BUN), uric acid, creatinine, sodium,
potassium, chloride, calcium,magnesium, iron, inorganic phos-
phate, total cholesterol (T-Cho), high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-
C), triacylglycerol, free fatty acid (FFA), phospholipid (PL), glucose,
hemoglobin A1c (HbA1c), insulin, acetoacetic acid,
3-hydroxybutyric acid, and total ketone body. In addition, leptin,
adiponectine, retinol-binding protein (RBP), des-acylghrelin, and
high sensitivity TNF-α, oxidized low-density lipoprotein, lipid
hydroperoxide, and serum pentosidine were tested at 0 and
12 weeks.All subjects were instructed to visit themedical center
after at least 10 h of fasting over the previous night to mini-
mize any extraneous dietary influences on the test results.
Urine test strips were used to detect protein, glucose, uro-
bilinogen and occult blood.These results of each subject were
expressed as false-positive (±) or positive (1+, 2+, 3+).
The subjects were asked to record all foods and beverages
consumed for 3 days before each visit. Nutritional analysis was
conducted by dieticians to calculate daily intake of energy,
protein, fat, carbohydrate, saturated fatty acid, unsaturated fatty
acid, cholesterol and dietary fibre.The amount of exercise was
calculated by the numbers of walking steps recorded with a
pedometer for 3 days before each visit except for week 2.
2.4. Statistical analyses
All the valuesmeasured are shownas themean ± standard error
of the mean (SEM).The physical examinations, hematological
examinations,urine specific gravity,nutrient intake andnumber
of walking steps were compared between the groups by the
unpaired Student’s t-test. Bonferronimultiple comparison test
was used to compare baseline values and values during the
treatment and observation periods in each group. For physical
examination, repeated two-wayANOVAwasused to assess time-
by-treatment interaction. Urine glucose, protein, urobilinogen
and occult blood were compared between the groups by using
theMann–WhitneyU-test.Wilcoxon t-testwas used to compare
baseline values and values during the treatment and obser-
vation periods in each group. A risk factor of p < 0.05 was
considered statistically significant.
3. Results and discussion
None of the subjects in this study were excluded based on the
exclusion criteria, a criteria to exclude the test subjects based
on abnormal blood, physical parameters, irregular lifestyles,
or being judged as unfit by the principle investigator.
3.1. Physical examination
Data on physical examination are shown in Fig. 1 and Table 2.
Hip circumference decreased significantly in the RSS group at
weeks 4, 8 and 12 compared to week 0 and body weight, BMI,
body fat ratio and waist circumference decreased signifi-
cantly at weeks 8 and 12 compared to week 0. Diastolic blood
pressure decreased significantly in the RSS group at week 12
compared to week 0 and by comparison with the control group.
Although a tendency to “return to an original condition” in
terms of body weight was seen during the observation period
in the RSS group, we believe our findings demonstrate that con-
tinuous consumption of RSS can control weight gain. Moreover,
discontinuing the consumption of RSS appears to return the
subject to his/her original condition without any measurable
damage to organs or tissues.
The anti-obesity activity of RSS is thought to be caused by
rare sugars present in the preparation. One of the bioactive in-
gredients contained in RSS is allulose. In the current study, RSS
made from HFCS contained 6% allulose, which was sufficient
to limit the accumulation of visceral fat during the intake of
caloric sweetener.
Fig. 1 – Amount of changes in body weight (A), body fat ratio (B) and waist circumference (C) during a 12-week treatment
period and 4-week observation period in slightly obese human subjects. Values are expressed as mean ± SEM. Significant
differences were shown: ##p < 0.01, ###p < 0.001 between two groups by unpaired t-test and *p < 0.05, **p < 0.01, ***p < 0.001,
at 0 week vs. 2, 4, 8, 12, 16 week by Bonferroni’s multiple comparison test.
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There are several possible mechanisms for the observed anti-
obesity activity elicited by allulose. One of the mechanisms
involves allulose induced activation of glucokinase transloca-
tion in the liver that facilitates glycogen biosynthesis (Toyoda
et al., 2010). The effect of glycogen synthesis from glucose in
the liver is to restrict glucose usage, which promotes the me-
tabolism of fat as an energy source. Ochiai, Onishi, Yamada,
Iida and Matsuo (2014) reported that the inclusion of allulose
in the diet of rats increased their energy expenditure, which
might be induced by enhanced fat metabolism initiated by glu-
cokinase translocation.
Other saccharides present in RSS, such as allose and sorbose,
also have the potential to suppress an increase in abdominal
fat. There were many reports suggesting that allose reduces
oxidative stress (Kimura et al., 2005); one mechanism being de-
creased expression of NADPH oxidase. These effects may
contribute to an amelioration of insulin resistance. Sorbose was
reported to suppress the activity of α-glucosidase (sucrase and
maltase) and to decrease serum insulin levels (Yamada et al.,
2014). Co-administration of both glucose and fructose is known
to lead to more energy expenditure than a single administra-
tion of glucose or fructose (Blaak & Saris, 1996).Though adequate
intake amount of RSS is thought to be an important factor, an
appropriate balance of these sugars in RSS may have contrib-
uted to the observed reduction in body weight and body fat
in this study.
3.2. Hematological examination
As shown in Table 3, though slight variances were observed
in some parameters, there were no abnormalities in hepatic
function, renal function or blood parameters. These signifi-
cant variations in hematological parameters were within the
standard range. In particular, intake of test carbohydrates did
not increase HbA1c value and oxidation of serum lipid in either
of the groups.
In the control group, cholinesterase, hemoglobin, potas-
sium, magnesium and chloride were significantly different at
intake or observation periods compared to week 0. The RSS
group displayed a significant increase in white blood cells at
week 4 (RSS; 6876.5 ± 577.7/µl, control; 5505.9 ± 296.2/µl, p < 0.05)
and decrease in sodium at the observation period (RSS;
140.4 ± 0.4 mEq/l, control; 141.5 ± 0.4 mEq/l, p < 0.05) com-
pared to the control group.
The variations of obesity markers (leptin, adiponectin, RBP,
des-acylghrelin and TNF-α) are shown in Fig. 2. RBP de-
creased significantly in the RSS group at week 12 compared
to week 0. Leptin in the RSS group increased significantly over
the same period. Des-acylghrelin increased significantly in both
the control group and the RSS group. Leptin is known to be
an appetite-suppressing hormone that increases energy me-
tabolism. RBP is reported to be an insulin-resistant cytokine
that is highly expressed in visceral fat (Klöting et al., 2007).The
Table 2 – Alteration in physical parameters during treatment of either the RSS or control drinks for 12 weeks and after
the observation periods.
Item Week 0 Week 2 Week 4 Week 8 Week 12 Observation p-value time ×
treatment
Weight (kg) p < 0.001
Control 70.36 ± 2.47 70.12 ± 2.43 70.13 ± 2.44 70.51 ± 2.46 70.52 ± 2.43 70.12 ± 2.43
RSS 70.24 ± 3.03 69.98 ± 3.05 69.74 ± 3.04 69.02 ± 3.00*** 68.39 ± 3.04*** 69.43 ± 3.02*
BMI p < 0.001
Control 25.57 ± 0.59 25.48 ± 0.58 25.49 ± 0.59 25.63 ± 0.61 25.63 ± 0.58 25.49 ± 0.58
RSS 25.42 ± 0.59 25.32 ± 0.59 25.24 ± 0.60 24.98 ± 0.59*** 24.74 ± 0.59*** 25.13 ± 0.60*
Body fat ratio (%) p < 0.001
Control 28.39 ± 1.72 28.45 ± 1.75 28.22 ± 1.73 28.21 ± 1.78 28.41 ± 1.73 27.82 ± 1.72
RSS 28.16 ± 2.12 27.61 ± 2.07 27.56 ± 2.07 26.73 ± 2.04** 26.44 ± 2.04*** 27.41 ± 2.11
Waist circumference
(cm)
p < 0.001
Control 83.87 ± 2.59 83.69 ± 2.59 83.38 ± 2.55 83.72 ± 2.56 83.42 ± 2.54 83.51 ± 2.49
RSS 84.72 ± 2.73 84.39 ± 2.77 83.87 ± 2.67 83.26 ± 2.68** 82.75 ± 2.67*** 83.79 ± 2.68
Hip circumference (cm) p < 0.01
Control 95.92 ± 1.48 95.78 ± 1.46 95.78 ± 1.50 95.74 ± 1.52 95.45 ± 1.49 95.68 ± 1.53
RSS 98.90 ± 2.15 98.66 ± 2.16 98.35 ± 2.14* 97.75 ± 2.16* 97.31 ± 2.14*** 98.40 ± 2.11
Systolic blood
pressure (mmHg)
Control 122.80 ± 2.50 122.70 ± 2.70 121.20 ± 2.60 121.90 ± 2.40 121.90 ± 2.40 122.50 ± 2.60
RSS 117.70 ± 3.30 118.50 ± 3.10 117.00 ± 3.20 117.60 ± 3.40 117.10 ± 2.90 120.60 ± 2.50
Diastolic blood
pressure (mmHg)
Control 76.90 ± 2.30 76.70 ± 2.10 76.20 ± 2.20 74.40 ± 2.50 74.50 ± 2.40 # 75.10 ± 2.40
RSS 74.30 ± 2.00 74.10 ± 2.10 72.60 ± 2.00 70.60 ± 1.80 68.20 ± 1.60* 71.80 ± 1.70
Values are expressed as mean ± SEM.
p-value for time-by-treatment interaction was assessed by repeated two-way ANOVA.
*p < 0.05, **p < 0.01, ***p < 0.001: Significantly different from 0 week (Bonferroni’s multiple comparison test).
# p < 0.05: Significantly different between two groups (unpaired t-test).
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Table 3 – Alteration in hematological parameters during treatment of either the RSS or control drinks for 12 weeks and after the observation periods.
Item Standard range Week 0 Week 2 Week 4 Week 8 Week 12 Observation
ALP (U/l)
Control 115–359 205.2 ± 10.9 202.2 ± 9.8 199.4 ± 9.6 201.3 ± 8.1 199.5 ± 11.1 195.1 ± 10.6
RSS 203.4 ± 14.2 190.9 ± 12.4 195.5 ± 13.4 201.2 ± 13.3 191.6 ± 11.4 192.9 ± 12.1
AST (U/l)
Control 10–40 18.6 ± 0.9 18.1 ± 0.9 18.2 ± 0.9 17.7 ± 1.0 17.2 ± 0.9 17.3 ± 0.9
RSS 19.4 ± 1.2 19.3 ± 1.1 18.1 ± 1.0 18.8 ± 0.9 18.9 ± 1.1 18.8 ± 0.9
ALT (U/l)
Control 5–40 18.9 ± 1.6 18.6 ± 1.5 18.2 ± 1.5 17.9 ± 1.4 17.8 ± 1.4 14.9 ± 1.0
RSS 19.5 ± 1.7 17.7 ± 1.8 17.0 ± 1.6 17.9 ± 1.6 17.2 ± 1.5 16.8 ± 1.4
LDH (U/l)
Control 115–245 168.6 ± 4.9 153.8 ± 4.0*** 161.0 ± 4.3 156.6 ± 5.3* 163.4 ± 4.2 157.8 ± 5.4
RSS 174.8 ± 8.0 169.1 ± 8.1 154.4 ± 7.4* 161.5 ± 7.0 167.6 ± 8.8 162.3 ± 7.5
γ-GTP (U/l) M: ≦70
F: ≦30Control 31.2 ± 4.3 30.4 ± 5.0 29.4 ± 4.6 35.0 ± 6.6 31.7 ± 5.3 29.4 ± 4.5
RSS 24.7 ± 3.4 22.0 ± 2.6 23.0 ± 3.1 27.1 ± 4.0 25.4 ± 4.4 25.9 ± 4.1
CPK (U/l) M: 62–287
F: 45–163Control 95.2 ± 9.1 # 85.1 ± 6.4 ## 106.8 ± 13.0 92.9 ± 7.0 92.1 ± 8.2 # 106.4 ± 22.4
RSS 137.5 ± 14.9 151.8 ± 21.2 132.1 ± 16.9 122.2 ± 13.7 156.9 ± 29.0 142.8 ± 20.1
TP (g/dl) 6.7–8.3
Control 7.41 ± 0.08 7.25 ± 0.09 7.28 ± 0.08 7.31 ± 0.09 7.27 ± 0.13 7.30 ± 0.11
RSS 7.41 ± 0.11 7.26 ± 0.08 7.29 ± 0.09 7.28 ± 0.08 7.29 ± 0.10 7.35 ± 0.10
Alb (g/dl) 4.0–5.0
Control 4.72 ± 0.06 4.61 ± 0.05 4.62 ± 0.05 4.63 ± 0.05 4.64 ± 0.07 4.61 ± 0.06
RSS 4.59 ± 0.10 4.48 ± 0.08 4.52 ± 0.08 4.51 ± 0.09 4.54 ± 0.09 4.56 ± 0.08
A/G
Control 1.77 ± 0.07 1.79 ± 0.07 1.78 ± 0.07 1.78 ± 0.08 1.81 ± 0.08 1.75 ± 0.06
RSS 1.65 ± 0.06 1.63 ± 0.06 1.66 ± 0.06 1.66 ± 0.05 1.66 ± 0.05 1.68 ± 0.06
Total bilirubin (mg/dl) 0.3–1.2
Control 0.73 ± 0.09 0.69 ± 0.05 0.72 ± 0.07 0.78 ± 0.06 0.78 ± 0.05 0.71 ± 0.06
RSS 0.61 ± 0.07 0.69 ± 0.08 0.70 ± 0.08 0.79 ± 0.10 0.72 ± 0.10 0.71 ± 0.07
Direct bilirubin (mg/dl) ≦0.4
Control 0.21 ± 0.02 0.18 ± 0.02 0.19 ± 0.02 0.21 ± 0.01 0.23 ± 0.02 0.20 ± 0.02
RSS 0.18 ± 0.02 0.18 ± 0.02 0.19 ± 0.03 0.21 ± 0.03 0.23 ± 0.03 0.21 ± 0.02
Indirect bilirubin (mg/dl) ≦0.8
Control 0.52 ± 0.06 0.51 ± 0.04 0.53 ± 0.05 0.57 ± 0.05 0.55 ± 0.04 0.51 ± 0.04
RSS 0.44 ± 0.05 0.51 ± 0.06 0.51 ± 0.06 0.58 ± 0.08 0.49 ± 0.07 0.50 ± 0.05
Uric acid (mg/dl) M: 3.7–7.0
F: 2.5–7.0Control 5.15 ± 0.29 4.99 ± 0.27 4.88 ± 0.27 5.05 ± 0.30 5.10 ± 0.28 4.90 ± 0.26
RSS 5.29 ± 0.32 4.92 ± 0.31 5.02 ± 0.33 5.06 ± 0.27 5.04 ± 0.30 5.05 ± 0.29
BUN (mg/dl) 8.0–22.0
Control 13.65 ± 0.81 12.05 ± 0.35 13.45 ± 0.57 # 13.42 ± 0.66 13.39 ± 0.72 13.34 ± 0.74
RSS 12.18 ± 0.61 12.09 ± 0.59 11.82 ± 0.48 12.15 ± 0.60 11.86 ± 0.58 12.27 ± 0.79
Creatinine (mg/dl) M: 0.61–1.04
F: 0.47–0.79Control 0.665 ± 0.024 0.666 ± 0.025 0.651 ± 0.028 0.672 ± 0.023 0.684 ± 0.029 0.671 ± 0.026
RSS 0.718 ± 0.026 0.706 ± 0.023 0.718 ± 0.022 0.728 ± 0.024 0.712 ± 0.024 0.717 ± 0.020
(continued on next page)
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Table 3 – (continued)
Item Standard range Week 0 Week 2 Week 4 Week 8 Week 12 Observation
Triglyceride (mg/dl) 50–149
Control 90.2 ± 14.8 96.9 ± 13.7 87.4 ± 9.5 86.6 ± 11.2 103.8 ± 15.9 88.4 ± 15.7
RSS 99.3 ± 11.9 94.4 ± 11.4 86.2 ± 12.6 92.2 ± 12.0 90.0 ± 12.4 97.9 ± 13.8
T-Cho (mg/dl) 150–219
Control 209.1 ± 9.3 205.2 ± 7.0 # 207.9 ± 6.5 # 212.9 ± 7.0 ## 203.9 ± 7.1 # 197.1 ± 7.3
RSS 190.1 ± 7.3 182.1 ± 6.2 185.6 ± 6.7 184.9 ± 5.4 182.1 ± 6.7 181.5 ± 5.9
LDL-C (mg/dl) 70–139
Control 121.4 ± 8.8 115.9 ± 6.0 119.9 ± 5.8 122.6 ± 5.8 116.4 ± 6.1 110.7 ± 6.0
RSS 108.2 ± 6.8 106.4 ± 5.1 108.2 ± 5.2 106.5 ± 5.6 106.1 ± 6.3 101.9 ± 5.4
HDL-C (mg/dl) M: 40–86
F: 40–96Control 65.6 ± 3.8 66.2 ± 4.1 66.9 ± 4.7 69.5 ± 5.8 68.1 ± 5.4 63.7 ± 4.6
RSS 62.7 ± 3.4 57.4 ± 2.6 60.8 ± 3.5 60.0 ± 3.0 61.2 ± 3.3 60.4 ± 3.7
FFA (µEq/dl) 140–850
Control 590.5 ± 59.7 419.0 ± 45.3 462.1 ± 66.3 442.4 ± 59.6 484.8 ± 47.0 446.6 ± 59.3
RSS 489.0 ± 40.4 470.2 ± 56.6 453.9 ± 50.7 455.8 ± 51.1 517.3 ± 66.2 514.4 ± 55.5
PL (mg/dl) 160–260
Control 217.4 ± 8.3 212.6 ± 6.6 215.2 ± 6.4 220.4 ± 7.2 # 217.8 ± 7.4 211.2 ± 8.4
RSS 206.2 ± 6.0 196.5 ± 6.2 202.0 ± 6.3 202.3 ± 5.1 199.6 ± 6.6 203.3 ± 6.4
Glucose (mg/dl) 70–109
Control 86.5 ± 2.5 87.5 ± 2.0 87.4 ± 1.2 86.8 ± 2.1 86.9 ± 2.5 85.4 ± 1.7
RSS 88.0 ± 2.1 86.2 ± 2.0 86.4 ± 1.9 88.8 ± 1.7 87.2 ± 1.6 86.5 ± 1.2
HbA1c (%) 4.3–5.8
Control 4.80 ± 0.05 4.84 ± 0.06 4.75 ± 0.05 4.68 ± 0.06 4.68 ± 0.05 4.76 ± 0.06
RSS 4.86 ± 0.07 4.85 ± 0.07 4.78 ± 0.07 4.75 ± 0.07 4.74 ± 0.08 4.73 ± 0.07
Insulin (µIU/ml) 1.84–12.2
Control 5.980 ± 0.760 6.101 ± 0.566 5.706 ± 0.609 5.239 ± 0.694 5.912 ± 0.716 5.413 ± 0.721
RSS 6.072 ± 0.741 5.698 ± 0.702 6.114 ± 0.851 6.455 ± 0.579 6.809 ± 0.953 5.552 ± 0.717
Acetoacetic acid (µmol/l) ≦55
Control 42.1 ± 10.4 16.5 ± 3.6 19.9 ± 5.1 21.5 ± 5.1 20.2 ± 4.5 22.6 ± 5.4
RSS 23.6 ± 5.4 24.5 ± 5.1 20.0 ± 7.6 23.7 ± 4.8 31.8 ± 9.5 23.7 ± 3.9
3-Hydroxybutyric acid (µmol/l) ≦85
Control 138.1 ± 43.9 44.9 ± 10.1 58.5 ± 16.4 58.8 ± 17.4 51.9 ± 13.9 69.2 ± 20.3
RSS 55.4 ± 15.6 62.6 ± 14.9 50.0 ± 19.3 49.6 ± 11.2 79.2 ± 29.8 69.6 ± 15.6
Total ketone body (µmol/l) ≦130
Control 180.2 ± 53.3 61.4 ± 13.7 78.4 ± 21.5 80.4 ± 22.4 72.1 ± 18.1 91.8 ± 25.5
RSS 79.0 ± 20.9 87.1 ± 19.9 70.0 ± 26.8 73.4 ± 15.8 111.1 ± 39.0 93.3 ± 19.4
Values are expressed as mean ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001: Significantly different from 0 week (Bonferroni’s multiple comparison test).
#p < 0.05, ##p < 0.01: Significantly different between two groups (unpaired t-test).
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improved changes in physical parameters associated with these
obesity-related factors demonstrate the potential of RSS as a
sweetener having the advantage of reducing visceral fat.
3.3. Urinalysis
Protein was detected in the urine of each subject in the control
group i.e., (±) at week 0 and the observation period. Each subject
in the RSS group gave a (±) result for protein in the urine at
week 0, (1+) at week 8 and (±) at week 12. For the occult blood
test, positive or false-positive markers in the control group were
detected as (±, ±) at week 0, (±, 2+) at week 2, (2+) at week 4,
(±, ±, 2+) at week 8 and (±, ±, ±) at the observation period.These
markers in the RSS group were detected as (1+) at week 0, (±)
at week 4, (±, ±) at week 8 and (±) at the observation period.
Glucose and urobilinogen were not detected in the urine
samples from any of the subjects. No significant changes were
observed in any of the urine parameters.
3.4. Consultations
The daily nutrient intake (energy, fat, protein, carbohydrate)
and number of walking steps for each group are indicated in
Table 4 and no significant changes were observed in these pa-
rameters. Also, no significant differences were shown in the
other nutrient intake (saturated fatty acid, unsaturated fatty
Fig. 2 – Changes in leptin (A), RBP (B), adiponectin (C), des-acyl ghrelin (D) and TNF-α (E) during treatment of either the RSS
or control drinks for 12 weeks. Values are expressed as mean ± SEM. Significant differences of 12 week from 0 week are
shown: *p < 0.05, **p < 0.01, ***p < 0.001 by paired t-test.
Table 4 – Alteration in daily intake of energy and nutrient factors, and exercise amount during treatment of either the
RSS or control drinks for 12 weeks and after the observation periods.
Item Week 0 Week 2 Week 4 Week 8 Week 12 Observation
Intake energy (kcal)
Control 1715.6 ± 60.4 1676.5 ± 55.9 1741.6 ± 60.3 1752.4 ± 66.0 1721.6 ± 68.8 1721.2 ± 55.4
RSS 1677.8 ± 52.6 1645.9 ± 64.0 1672.2 ± 74.1 1679.5 ± 51.5 1711.1 ± 47.2 1682.6 ± 52.8
Fat (g)
Control 63.0 ± 3.1 60.9 ± 2.6 62.7 ± 3.3 63.4 ± 2.3 63.4 ± 3.1 60.1 ± 2.5
RSS 65.0 ± 2.5 64.6 ± 2.8 62.7 ± 2.6 63.8 ± 2.5 64.3 ± 2.4 63.4 ± 2.8
Protein (g)
Control 53.8 ± 3.1 54.7 ± 2.6 56.4 ± 3.0 54.6 ± 3.2 52.7 ± 2.9 54.7 ± 2.8
RSS 52.9 ± 2.1 49.6 ± 2.7 53.4 ± 2.8 51.7 ± 2.1 54.0 ± 2.2 53.2 ± 2.5
Carbohydrate (g)
Control 230.9 ± 7.7 221.7 ± 7.0 231.4 ± 8.7 237.5 ± 9.5 233.6 ± 9.6 232.0 ± 7.9
RSS 223.2 ± 7.4 223.7 ± 8.7 221.9 ± 9.6 227.0 ± 8.2 229.0 ± 6.8 224.4 ± 8.3
Number of walking steps
Control 9623.9 ± 813.9 9632.1 ± 838.0 9616.9 ± 815.8 9616.4 ± 828.3 9622.4 ± 823.3
RSS 8900.7 ± 685.5 8908.2 ± 758.8 8865.5 ± 717.5 8922.1 ± 729.0 8834.1 ± 738.9
Values are expressed as mean ± SEM, and expressed as average 3 days before each visit.
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acid, cholesterol and dietary fiber). Moreover, no adverse events
directly related to RSS intake were reported during the period
of the study.
Appetite throughout the day is more important than tem-
porary calorie restriction resulting in a larger appetite. The
appetite of both glucose and fructose are affected by the rate
of ATP/AMP turnover (Lane & Cha, 2009). In terms of allulose,
the amount of the food intake is closely related to body weight
in some animal experiments involving the feeding of this sugar
(Matsuo & Izumori, 2006; Ochiai et al., 2014). In the current clini-
cal trial, there was no difference in the daily nutrient intake
between the RSS and control groups as reflected by the value
of des-acylghrelin (Fig. 2). Because subjects took only 3 day
records before the experimental day, differences between the
groups might not have been detected.
4. Conclusions
In the current human trial, the efficacy and safety of ingest-
ing new sweetener “RSS” over a 12-week period were
investigated by a randomized double-blind parallel experi-
ment for the first time. Significant reductions of body weight,
body fat percentage and waist circumference in the rare sugar
syrup group were observed compared to the high fructose corn
syrup group.We also confirmed that no adverse effects or ab-
normal blood parameters were observed with regard to lipid
and carbohydrate metabolism, hepatic and renal functions. RSS
also gives natural sweetness, which resembles that of sucrose,
even if combined with high intensity sweetener, such as stevia,
sucralose, acesulfame-K or aspartame, because of its supe-
rior masking ability. A calorie sweetener blended with RSS and
high intensity sweeteners might be a highly effective means
of countering obesity.
Acknowledgments
The production method of RSS was established by the support
of Regional Innovation Creation R&D Programs, Ministry of
Economy,Trade and Industry, Japan.We are grateful to Dr. Ken
Izumori in Rare Sugar Research Center at Kagawa University
for the instruction in this program.We also wish to thank all
the volunteers who participated in this study as well as the
team of medical scientists in the Faculty of Medicine at Kagawa
University.
R E F E R E N C E S
Blaak, E. E., & Saris, W. H. (1996). Postprandial thermogenesis and
substrate utilization after ingestion of different dietary
carbohydrates.Metabolism: Clinical and Experimental, 45, 1235–
1242.
Chung, M. Y., Oh, D. K., & Lee, K. W. (2012). Hypoglycemic health
benefits of D-psicose. Journal of Agricultural and Food Chemistry,
60, 863–869.
Gross, L. S., Li, L., Ford, E. S., & Liu, S. (2004). Increased
consumption of refined carbohydrates and the epidemic of
type 2 diabetes in the United States: An ecologic assessment.
The American Journal of Clinical Nutrition, 79, 774–779.
Iida, T., Yamada, T., Hayashi, N., Okuma, K., Izumori, K., Ishii, R., &
Matsuo, T. (2013). Reduction of abdominal fat accumulation in
rats by 8-week ingestion of a newly developed sweetener
made from high fructose corn syrup. Food Chemistry, 138, 781–
785.
Kimura, S., Zhang, G. X., Nishiyama, A., Nagai, Y., Nakagawa, T.,
Miyanaka, H., Fujisawa, Y., Miyatake, A., Nagai, T., Tokuda, M.,
& Abe, Y. (2005). D-allose, an all-cis aldo-hexose, suppresses
development of salt-induced hypertension in Dahl rats.
Journal of Hypertension, 23, 1887–1894.
Klöting, N., Graham, T. E., Berndt, J., Kralisch, S., Kovacs, P.,
Wason, C. J., Fasshauer, M., Schön, M. R., Stumvoll, M., Blüher,
M., & Kahn, B. B. (2007). Serum retinol-binding protein is more
highly expressed in visceral than in subcutaneous adipose
tissue and is a marker of intra-abdominal fat mass. Cell
Metabolism, 6, 79–87.
Lane, M. D., & Cha, S. H. (2009). Effect of glucose and fructose on
food intake via malonyl-CoA signaling in the brain.
Biochemical and Biophysical Research Communications, 382, 1–5.
Matsuo, T., Baba, Y., Hashiguchi, M., Takeshita, K., Izumori, K., &
Suzuki, H. (2001). Dietary D-psicose, a C-3 epimer of
D-fructose, suppresses the activity of hepatic lipogenic
enzymes in rats. Asia Pacific Journal of Clinical Nutrition,
10, 233–237.
Matsuo, T., Ishii, R., Iida, T., Yamada, T., Takamine, S., &
Shirai, Y. (2011). Ninety-day oral toxicity study of rare sugar
syrup in maleWistar rats. Current Topics in Toxicology,
7, 41–49.
Matsuo, T., & Izumori, K. (2006). Effects of dietary D-psicose on
diurnal variation in plasma glucose and insulin
concentrations of rats. Bioscience, Biotechnology, and
Biochemistry, 70, 2081–2085.
Matsuo, T., & Izumori, K. (2009). D-psicose inhibits intestinal
alpha-glucosidase and suppresses the glycemic response
after ingestion of carbohydrates in rats. Journal of Clinical
Biochemistry and Nutrition, 45, 202–206.
Ochiai, M., Onishi, K., Yamada, T., Iida, T., & Matsuo, T. (2014).
D-psicose increases energy expenditure and decreases body
fat accumulation in rats fed a high-sucrose diet. International
Journal of Food Sciences and Nutrition, 65, 245–250.
Osaki, S., & Yoshino, Z. (1982). Analysis method of maltulose in
high-fructose syrup. Journal of the Japanese Society of Starch
Science, 29, 210–215.
Shiraishi, F., Kawakami, K., & Kusunoki, K. (1985). Kinetics of
condensation of glucose into maltose and isomaltose in
hydrolysis of starch by glucoamylase. Biotechnology and
Bioengineering, 27, 498–502.
Swithers, S. E. (2013). Artificial sweeteners produce the
counterintuitive effect of inducing metabolic derangements.
Trends in Endocrinology and Metabolism, 24, 431–441.
Toyoda, Y., Mori, S., Umemura, N., Nimura, Y., Inoue, H., & Hata, T.
(2010). Suppression of blood glucose levels by D-psicose in
glucose tolerance test in diabetic rats. Japanese Pharmacology
and Therapeutics, 38, 261–269.
Toyota, S., Fukushi, Y., Katoh, S., Orikasa, S., & Suzuki, Y. (1989).
Anti-bacterial defense mechanism of the urinary bladder.
Role of mannose in urine. The Japanese Journal of Urology, 80,
1816–1823.
Yamada, T., Hayashi, N., Iida, T., Takamine, S., Okuma, K., &
Matsuo, T. (2014). Dietary D-sorbose decreases serum insulin
levels in growing Sprague-Dawley rats. Journal of Nutritional
Science and Vitaminology, 60, in press.
Yamada, T., Iida, T., Hayashi, N., Oga, H., Okuma, K., & Izumori, K.
(2010). Effects of D-psicose on body fat accumulation and high
fructose corn syrup diets in rats. Journal of the Japanese Society
for Food Science and Technology, 57, 263–267.
159j o u rna l o f f un c t i ona l f o od s 1 1 ( 2 0 1 4 ) 1 5 2 – 1 5 9
